Source comparison
CJC-1295 vs MK-677: Research Application Comparison
Mechanism GHRH analog. Amplifies pulsatile GH release via pituitary GHRH receptors Ghrelin receptor agonist. Continuous GH and IGF-1 elevation via GHS-R1a binding CJC-1295 preserves natural pulse rhythm; MK-677 creates sustained elevation that may desensitise
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH analog. Amplifies pulsatile GH release via pituitary GHRH receptors
- Ghrelin receptor agonist. Continuous GH and IGF-1 elevation via GHS-R1a binding
- CJC-1295 preserves natural pulse rhythm; MK-677 creates sustained elevation that may desensitise over time
- Administration
- Subcutaneous injection, 1–3× per week
- Oral capsule or solution, once daily
- MK-677 offers dosing convenience; CJC-1295 requires injection but maintains physiological GH patterns
- Half-Life
- 6–8 days (with DAC); 30 min–2 hrs (without DAC)
- 4–6 hours
- CJC-1295 with DAC allows weekly dosing; MK-677 requires daily administration due to short half-life
- GH Secretion Pattern
- Pulsatile. Mirrors endogenous circadian rhythm
- Sustained baseline elevation throughout 24-hour cycle
- Pulsatile patterns preserve negative feedback loops; continuous elevation risks blunted response
- IGF-1 Impact
- Indirect. GH stimulates hepatic IGF-1 synthesis
- Direct. Elevates both GH and IGF-1 simultaneously
- MK-677 shows faster IGF-1 response in some models; CJC-1295 requires 2–4 weeks for peak IGF-1 elevation
- Receptor Downregulation Risk
- Low. Works through natural GHRH pathway
- Moderate. Sustained ghrelin receptor activation may reduce sensitivity in long protocols
- CJC-1295 less prone to tolerance; MK-677 may require cycling to maintain efficacy beyond 12 weeks
- Typical Research Dose
- 1–2 mg/week (DAC); 100–300 mcg 2–3×/day (non-DAC)
- 10–25 mg/day orally
- Dosing precision is critical. Under-dosing reduces efficacy; over-dosing doesn't scale linearly with GH output